On December 18th, VCBeat “2018 Future Medical VB 100” Forum was held in Beijing.

As the largest medical event at the end of the year, the forum brought together more than 4,000 representatives from government agencies, 3 A hospitals, listed companies, medical industry unicorns, well-known media agencies and other organizations. More than 100 industry experts visited the site, and hundreds of thousands of Internet users watched the live broadcast online. The scale of the forum is grand and unprecedented.

It is learned that Future Medical VB 100 was founded in 2015. It is the first domestic list in the innovative medical field for non-listed companies launched by VCBeat and VCBeat Research (VBR). It aims to select Chinese innovative medical enterprises that truly represent future medical industry, find the core power of China’s future medical industry, and promote the process of innovation and reform in the medical industry.

With the brand influence that has been fostered through many years of efforts in the field of personalized medicine for cancer and the innovative integration practice by continuously seeking innovation and changes, ACCB surpassed more than one thousand medical enterprises and was successfully listed in the “2018 Future Medical VB 100”.

▲Vice President HE Huanrong (third from left) received the award on the stage 

Mr. HE Huanrong, Vice President of Tus-S&T Service Group and Chief Operating Officer of ACCB attended the awards dinner held in the evening and received the award on the stage.

Through fourteen years of down-to-earth efforts, ACCB distinguished itself in 2018. As a pioneer, observer and practitioner in the precision medicine industry, ACCB has, in its so many years’ development, always adhered to the brand belief of “seeking development by professionalism and winning by quality”, continuously improved detection technology in a down-to-earth manner, conscientiously strengthened service quality, and established a brand DNA representing the unique properties of ACCB in the field of gene detection. Meanwhile, under the guidance of the “One Body and Two Wings” strategy, it actively promotes the transformation of advanced technological achievements in the biotechnology field through continuous innovation in technology and business models, accelerates the coverage of the network of regional medical detection centers and the transfer of high-quality resources to grass-roots level through continuously optimizing the integration of medical resources and the mechanism of joint construction and sharing, and injects new vitality, new power and new opportunities into its detection business through continuous docking with cutting-edge technologies such as artificial intelligence. By staying true to the mission and making great efforts, it has achieved high-quality medical and health services with a lower cost and greater accessibility to benefit the public!